Changchun Hi-Tech (000661.SZ): Jinsai Pharmaceutical's application for registration of domestically produced drugs for GS3-007a dry suspension was approved

Zhitongcaijing · 11/14/2025 13:49

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, the company's holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”) received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registration of domestically produced drugs for GS3-007a dry suspension was approved. GS3-007a dry suspension is an oral small-molecule growth hormone secretion-promoting drug independently developed by Jinsai Pharmaceutical. It is registered as a chemical class 1 and is intended for the treatment of slow growth (PGHD) in children caused by endogenous growth hormone deficiency. Up to now, there are no similar products on the market in China. The approval of this clinical trial application can promote subsequent clinical development of this product and meet the unmet clinical needs of patients.